Cubist expands hospital sales force
Cubist will begin increasing its anti-infective acute care U.S. sales force from 99 to 135 reps immediately, the firm announced Nov. 22. The expansion follows a Nov. 21 decision by FDA to grant priority review to the company's sNDA for Cubicin in treatment of endocarditis and bacteremia caused by Staphylococcus aureus (1"The Pink Sheet" March 7, 2005, p. 39). The sales realignment, effective Jan. 1, will focus on increasing coverage for the broadened indication...
You may also be interested in...
Cubist will increase its Cubicin (daptomycin) sales force by one third in the first quarter, bringing the total to 100 reps, CEO Michael Bonney said
Most clinical trial sponsors view data disclosure as a mandate, maintaining regulatory compliance as a legal requirement. Study sponsors that realize the potential to repurpose this data, using a patient-first approach, turn transparency into a strategic advantage for engagement and recruitment efforts.
The Bio-Console 560 extracorporeal blood pumping console is being recalled over reports it could lose power during bypass surgery, which could lead to organ or neural dysfunction, blood clots, or even death.